Our Parkinson's Place: Phase IIb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Sunday, July 5, 2015

Phase IIb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease

By News Staff | July 4th 2015

The Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease has been announced as a success.

P2B001 is a combination of low dose pramipexole and low dose rasagiline administered as a proprietary sustained release formulation. The study, titled A Phase IIb, Twelve Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjectswith Early Parkinson's Disease, showed that it met primary and secondary clinical endpoints for both dose combinations. Specifically, the results showed:

Overall improvement of 5.97 UPDRS points for the high dose combination, leading to a significant change of 4.67 UPDRS points compared to placebo (P<0.001)
Overall improvement of 5.14 UPDRS points in the low dose combination, leading to a significant change of 3.84 UPDRS units compared to placebo (P<0.001)
A favorable safety profile

One hundred and forty-nine patients participated in the study which was conducted at 29 clinical sites throughout the US and Israel. C. Warren Olanow, M.D., Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine in New York and CEO of Clintrex LLC, and Karl Kieburtz, M.D., Professor of Neurology, Public Health Science and Environmental Medicine at the University of Rochester and President of Clintrex LLC were the clinical leaders of the study.

An estimated seven to ten million people worldwide are living with Parkinson's disease (PD), a neurodegenerative disorder of the central nervous system. The cardinal symptoms of PD include: tremors, slowed movement (bradykinesia), rigid or stiff muscles, and impaired posture, balance, and walking.

The current gold standard treatment for treating PD is Levodopa, but long term use of Levodopa is associated with severe side effects over time, that include dyskinesia (uncontrolled involuntary movement) and off periods (hours of time when the patient suffers from a return of parkinsonian features). To delay this situation, physicians often prescribe other drugs at the early stage of the illness to delay the introduction of levodopa.

Though these drugs are not associated with motor complications, they are not as effective as Levodopa and can result in serious unwanted side effects. Therefore, there is an unmet medical need for a safe and effective treatment of early PD that allows a delay in the introduction of Levodopa and the risk of Levodopa associated motor complications.

"Pharma Two B's P2B001 combines two non-Levodopa drugs that have been individually approved for the treatment of early stage Parkinson's disease, in a sustained release profile. Given as low dose monotherapies, the anti-Parkinsonian effect of these drugs given individually is limited, while in higher doses they can be associated with potentially serious side effects. In preclinical studies, we observed that a low dose combination of these two drugs administered in a sustained release formulation has synergistic effects leading to notable efficacy and a very good safety profile," said Dr. Nurit Livnah, CEO of Pharma Two B Ltd.

http://health.einnews.com/article/274256729/Z1wVzCMZtGEPxKZn